Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Expands By 30.8%

Genenta Science S.p.A. (NASDAQ:GNTA) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,400 shares, an increase of 30.8% from the January 15th total of 2,600 shares. Based on an average daily trading volume, of 10,600 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Allianz SE purchased a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned approximately 0.56% of Genenta Science as of its most recent filing with the SEC. Institutional investors own 15.13% of the company’s stock.

Genenta Science Price Performance

NASDAQ GNTA traded up $0.55 during mid-day trading on Friday, reaching $4.37. 6,022 shares of the stock were exchanged, compared to its average volume of 10,297. The stock has a 50 day simple moving average of $4.46 and a 200-day simple moving average of $4.59. Genenta Science has a one year low of $2.20 and a one year high of $7.28.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.